LJN Newsletters

This article provides an overview of case law holding that insurance companies are obligated to provide coverage for trademark claims under advertising injury coverage, even when the word "trademark" does not appear anywhere in the policy. Further, it discusses rulings on the prior publication exclusion, which insurers frequently assert applies to advertising injury in the trademark infringement context.

It's no secret that our clients are busy. From spa days to fancy dinners, they likely have more invitations for law firm networking events than they have the time (or the desire) to attend. This is especially true for our female clients, who often find their available time further compressed by obligations outside the office.

By investing your time, skills and money in volunteer efforts, you stand to benefit your own morale, while also making and furthering contacts that can be extremely helpful to your legal career, both now and down the road.

The goal of feedback is improved performance. Teams committed to giving honest, constructive, thoughtful, feedback are intelligent, self-correcting and constantly improving their individual and team performance.

Given the rising popularity of virtual worlds and the ability to generate real-world income from activities within the virtual realm, it is not surprising that the virtual marketplace is thriving and that trademark and copyright infringements occur on a regular basis.

What a year it has been and now once again, it is time for law firm marketing and communications departments to start thinking about their submissions for consideration to earn a spot on the coveted MLF 50 ' The Top 50 Law Firms in Marketing and Communications.

Is a "product by process" claim infringed by products that are made by other processes? After 17 years of waiting, the Federal Circuit emphatically answered the question: No; product-by-process claims are only infringed by products made using the claimed process. Although the law now appears to be clear, the strongly worded dissent questions the soundness of the ruling and warns of potentially far-reaching implications for the pharmaceutical and biotech industries.

Addressing the issue of whether a comprehensive reference listing of every relevant antisense oligodeoxynucleotide in a known nucleic acid sequence anticipates claims to specific antisense sequences, the U.S. Court of Appeals for the Federal Circuit held that anticipation merely requires that the oligonucleotide sequence was in the prior art, not that its usefulness was previously disclosed.